Virpath- Influenza, from emergence to control

Afficher tout

Research Themes

Emerging influenza viruses offer considerable threat to the overall global health of people and their economies, as evidenced by serial emergence of antigenically unique and highly pathogenic influenza strains over the past two decades. Importantly, respiratory viruses have considerable potential to spread rapidly across the globe, dictating an urgent need for new and rapid response strategies for effective containment and control.

The Virpath team proposes an integrative approach on a broad range of influenza virus facets from surveillance to control. We are organized in two interplaying groups (B Lina/PI and M Rosa-Calatrava/Co-PI) and work on different aspects of influenza virus biology, from the deciphering of the mechanisms leading to virus emergence and pathogenesis, to the analysis of viral interplays with cells and host factors during virus infection. We focus on (i) the understanding the role of the packaging signals harbored by viral gene segments during genetic reassortments, (ii) the importance of the functional balance between the two surface glycoproteins for infection and pathogenesis, (iii) and the virus-induced modification of specific cellular signaling pathways.

From a more translational point of view, we are also interested in the mechanisms of antiviral resistance, as well as the discovery innovative antiviral strategies targeting the host and optimization of vaccine quality as new means to control influenza infections. To that end, in addition to the long-standing basic skills to study influenza viruses, our laboratory has implemented new technical skills including Reverse Genetics, transcriptomic analysis of clinical specimens and a fully functional vaccine-antigen production and characterization platform. In addition, VirPath has strong connections with the National Influenza Reference Centre and the clinical research activities hosted by the Hospices Civils de Lyon. Importantly, a Technology Research Platform (VirNext) has been developed in order to enhance translational research and stimulate partnerships and transfer of technology towards the industry. Such connections resulted into a substantial portfolio of patents, the implementation of clinical trials and the founding of two companies (VirHealth and Signia Therapeutics).



Innovative nano DElivery systems for Influenza Antigens
2016 – CEA Leti ; Institut Albert Bonniot (IAB) U823 INSERM Université Grenoble

PHRC : FLUNEXT Clinical trial  
Confirmation of the Antiviral Effects of repurposed drugs.
Jan. 2016 – CHRU de Lille ; VirPath.
Triggersep label

ANR : Psi-FLU project
Sequence and structure of the packaging signals of the influenza A virus genome.
Sept. 2015 – IBMC Architecture et Réactivité de L’ARN CNRS UPR 9002

Purification of in vivo influenza virus crystalline structures in order to characterize the complete NS1 protein structure
2015 – IBS ; VirPath (Principal investigator)

ANR : OPTIVAC project
leveraging On cellular immune resPonse To Improve flu VACcines.
Jan. 2014 – Imaxio ; CIRI U1111 INSERM – UMR 5308 CNRS – ENS Lyon – UCBL1

ANR : BioVirSafe (LabCom) project
Laboratoire Commun de recherche et développement de biocides pour la maîtrise des contaminations microbiologique.
Jan. 2014 – PSA (Produits Sanitaires Aéronefs, Paris) ; VirPath (Principal investigator)

ANR-PRTS : Cov-Sign project
Identification of novel inhibitors against emerging human coronaviruses MERS-CoV and SARS-CoV from in vivo transcriptionnel.
Jan. 2014 – Institut Pasteur – CNRS UMR3569 ; CIIL Inserm U1019 CNRS UMR8204 ; CHRU de Lille ; ProfileXpert ; VirPath (Principal investigator)
Lyon Biopole label

FP7 Marie Curie actions: FLU-MAL VLP project
Chimeric Influenza-VLP used as vaccine platform for presentation of foreign antigens, application to Malaria antigens.
Jan. 2013 – VirPath (Principal investigator)

CMIRA program (Rhône-Alpes)
Programme de coopération structurante de la région Rhône-Alpes avec la région de Québec.
Jan. 2013  VirPath (Principal investigator)

PHRC : FLUMED Clinical trial (NCT01546506)
Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells.
Jan. 2012 – Hospices Civils de Lyon ; Université Claude Bernard Lyon 1 ; Virpath (Principal investigator)

FUI : COV-KO project
Réalisation d’appareils sécurisés (autonomes et intégrés) de traitement de l’air intérieur « 0 » COV, « 0 » odeur.
Jan. 2012 – BMES ; Brochier ; Tera Environnement ; ALDEBO ; ETHERA ; Atlantic ; IRCE Lyon UMR 5256 CNRS
Axelera Label

BQIP : VirNext platform
Bonus qualité relations industrielles plateformes 2012.
Jan. 2012 – VirNext ; Université Claude Bernard Lyon 1; Ezus

FUI : FLURIAD project
Mucous administration of anti-influenza vaccine.
Jan. 2011 – Onxeo ; Université Paris Sud EA 401; Sogeval ; Gredeco ; CHU de Nice.
Medicen label

APP Recherche Clinique Translationnelle : FLUNEXT project
Transcriptomic signature of influenza from pandemic H1N1 infected patients.
Jan. 2010 – Inserm ; DHOS

FUI : SAVAB project.
Anti-microbiologic systems.
Jan. 2010 – Aelovre.
Pegase label